Cybin (NASDAQ:HELP) Stock Crosses Below 200-Day Moving Average Following Weak Earnings

Cybin Inc. (NASDAQ:HELP – Get Free Report)’s stock price crossed below its two hundred day moving average during trading on Monday after the company announced weaker than expected quarterly earnings. The stock has a two hundred day moving average of $7.81 and traded as low as $6.90. Cybin shares last traded at $7.67, with a volume of 12,808,773 shares traded.

The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.74).

Analysts Set New Price Targets

Several equities analysts have commented on HELP shares. Wells Fargo & Company raised their target price on shares of Cybin from $16.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, October 22nd. Barclays initiated coverage on shares of Cybin in a research note on Friday, September 18th. They issued an “overweight” rating and a $35.00 price target for the company. Wall Street Zen lowered shares of Cybin from a “sell” rating to a “strong sell” rating in a research note on Saturday, November 7th. Finally, TD Cowen increased their price objective on shares of Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Six research analysts have rated the stock with a Buy rating. According to MarketBeat, Cybin has an average rating of “Buy” and a consensus target price of $47.33.

View Our Latest Analysis on HELP

Insider Buying and Selling

In related news, insider Eric H. L. So bought 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The shares were acquired at an average cost of $12.39 per share, for a total transaction of $1,239,000.00. Following the acquisition, the insider directly owned 4,465,014 shares of the company’s stock, valued at $55,321,523.46. The trade was a 2.29% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Greg Cavers bought 3,000 shares of the business’s stock in a transaction dated Tuesday, September 29th. The shares were bought at an average cost of $12.91 per share, for a total transaction of $38,730.00. Following the completion of the transaction, the chief financial officer directly owned 3,000 shares of the company’s stock, valued at $38,730. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have acquired 688,000 shares of company stock valued at $8,422,830. Insiders own 15.00% of the company’s stock.

Hedge Funds Weigh In On Cybin

A number of institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. purchased a new stake in Cybin during the third quarter valued at about $568,000. Great Point Partners LLC acquired a new position in shares of Cybin in the third quarter worth about $3,944,000. Integral Health Asset Management LLC acquired a new position in shares of Cybin in the third quarter worth about $6,145,000. Blue Owl Capital Holdings LP boosted its holdings in shares of Cybin by 381.2% in the third quarter. Blue Owl Capital Holdings LP now owns 288,282 shares of the company’s stock worth $3,543,000 after buying an additional 228,371 shares during the period. Finally, State Street Corp purchased a new position in shares of Cybin in the third quarter worth approximately $363,000. Hedge funds and other institutional investors own 17.94% of the company’s stock.

Cybin Stock Down 6.1%

The firm’s 50-day moving average price is $11.04 and its two-hundred day moving average price is $7.81.

About Cybin

(Get Free Report)

Cybin, which changed its name to Helus Pharma, is a clinical-stage biopharmaceutical company developing psychedelic-based treatments for mental health conditions. Its research focuses on designing and evaluating investigational compounds intended to address conditions including depression and anxiety disorders. The company’s pipeline has included CYB003, a deuterated psilocin analog being studied for major depressive disorder, and CYB004, an investigational DMT-based treatment studied for generalized anxiety disorder.

Further Reading

Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.